Mubritinib
Cat. No.：YN340134
CAS No. ：366017-09-6
| 产品名称: | Mubritinib |
| CAS No.: | 366017-09-6 |
| Chemical Name: | 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole |
| Synonyms: | 木利替尼; TAK-165 |
| 分子量: | 468.47 |
| 分子式: | C₂₅H₂₃F₃N₄O₂ |
| SMILES: | FC(C1=CC=C(/C=C/C2=NC(COC3=CC=C(CCCCN4N=NC=C4)C=C3)=CO2)C=C1)(F)F |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Mubritinib (TAK-165) 是有效，选择性的EGFR2/HER2抑制剂，IC50值为6 nM。 |
| IC50和靶点: | [{name:"HER2:6 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Nagasawa, J., Mizokami, A., Koshida, K., et al.Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivoInt. J. Urol.13(5),587-592(2006)
Sridhar, S.S., Seymour, L., and Shepherd, F.A.Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancerLancet Oncol.4(7),397-406(2003)
